VDJ-001
- Generic Name
- VDJ-001
Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis
Phase 3
Not yet recruiting
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Beijing VDJBio Co., LTD.
- Target Recruit Count
- 615
- Registration Number
- NCT06726096
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A First-in-human Study of a Novel Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 40
- Registration Number
- NCT06021574
- Locations
- 🇨🇳
the Affliated Hospital of Qingdao University, Qingdao, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath